Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.54 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991421 | 0.92 | AGTR1 (0.57) | AGTR2AGTR1 | |
| SCHEMBL10021559 | 0.92 | AGTR2 (0.57) | AGTR2AGTR1PPARG | |
| SCHEMBL12990879 | 0.91 | AGTR2 (0.53) | AGTR2AGTR1PPARG | |
| SCHEMBL12604965 | 0.90 | AGTR1 (0.60) | AGTR2AGTR1GP6 | |
| SCHEMBL668511 | 0.90 | AGTR1 (0.51) | AGTR2AGTR1PPARG | |
| SCHEMBL12990909 | 0.90 | AGTR2 (0.54) | AGTR2AGTR1 | |
| SCHEMBL16252278 | 0.89 | AGTR2 (0.58) | AGTR2AGTR1GP6 | |
| SCHEMBL12991377 | 0.89 | AGTR1 (0.64) | AGTR2AGTR1 | |
| Elisartan SCHEMBL489081 | 0.88 | AGTR1 (0.53) | AGTR2AGTR1PPARG | |
| Elisartan SCHEMBL489079 | 0.88 | AGTR1 (0.53) | AGTR2AGTR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143898-A1 | NEW CRYSTAL FORM OF COMPLEX OF ARB METABOLITE AND NEP INHIBITOR AND METHOD FOR PREPARATION THEREOF | 深圳信立泰药业股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-11026925-B2 | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite and preparation method thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO. LTD. (CN) | 2021-06-08 | — | — | US | disclosed |
| WO-2021093697-A1 | COMPOSITE OF ANGIOTENSIN II RECEPTOR ANTAGONIST AND NEP INHIBITOR AND PREPARATION METHOD THEREFOR | 深圳信立泰药业股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| US-20200061025-A1 | ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLITE AND NEP INHIBITOR COMPOSITE AND PREPARATION METHOD THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO. LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20170157095-A1 | ALLISARTAN ISOPROXIL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2017-06-08 | — | — | US | disclosed |
| US-20170157095-A1 | ALLISARTAN ISOPROXIL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2017-06-08 | — | — | US | disclosed |
| US-9670184-B2 | Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil | SHENZHEN SALUBRIS PHARMACEUTICALS CO. LTD (CN) | 2017-06-06 | — | — | US | disclosed |
| US-9670184-B2 | Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil | SHENZHEN SALUBRIS PHARMACEUTICALS CO. LTD (CN) | 2017-06-06 | — | — | US | disclosed |
| US-20170152243-A1 | ALLISARTAN ISOPROXIL POLYMORPH, ITS PREPARATION METHOD AND PHARMACEUTICAL | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152243-A1 | ALLISARTAN ISOPROXIL POLYMORPH, ITS PREPARATION METHOD AND PHARMACEUTICAL | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20100292286-A1 | Crystalline imidazole-5-carboxylic acid derivative | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2010-11-18 | — | — | US | disclosed |
| US-20100292286-A1 | Crystalline imidazole-5-carboxylic acid derivative | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2010-11-18 | — | — | US | disclosed |
| EP-2213669-A1 | CRYSTALLINE IMIDAZOL-5-CARBOXYLIC ACID DERIVATE | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2010-08-04 | — | — | EP | disclosed |
| US-20100168193-A1 | THERAPEUTIC USE OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2010-07-01 | — | — | US | disclosed |
| US-20100168193-A1 | THERAPEUTIC USE OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2010-07-01 | — | — | US | disclosed |
| EP-2157089-A1 | THE THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES | Shanghai Allist Pharmaceutical., Inc. (CN) | 2010-02-24 | — | — | EP | disclosed |
| US-20090326024-A1 | SALTS OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES, A METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-12-31 | — | — | US | disclosed |
| US-20090326024-A1 | SALTS OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES, A METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-12-31 | — | — | US | disclosed |
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | AGTR2, AGTR1, REN | AGTR2 1/4885AGTR1 2/4885GP6 2440/4885 |
| US-20100168193-A1 | THERAPEUTIC USE OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES | REN, TNNI3, AGTR1 | AGTR2 8/4885AGTR1 3/4885GP6 4056/4885 |
| US-20170157095-A1 | ALLISARTAN ISOPROXIL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION | PRSS8, ACE, CYP2C19 | AGTR2 29/4885AGTR1 56/4885GP6 1285/4885 |
| US-20090326024-A1 | SALTS OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES, A METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | CYP3A5, ADH5, WASHC5 | AGTR2 130/4885AGTR1 138/4885GP6 2380/4885 |
| US-11026925-B2 | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite and preparation method thereof | AGTR1, AGTR2, MME | AGTR2 2/4885AGTR1 1/4885GP6 945/4885 |
| US-20200061025-A1 | ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLITE AND NEP INHIBITOR COMPOSITE AND PREPARATION METHOD THEREOF | AGTR1, AGTR2, MME | AGTR2 2/4885AGTR1 1/4885GP6 945/4885 |
| US-20170152243-A1 | ALLISARTAN ISOPROXIL POLYMORPH, ITS PREPARATION METHOD AND PHARMACEUTICAL | PTGIR, REN, PTGER1 | AGTR2 12/4885AGTR1 18/4885GP6 964/4885 |
| US-20100292286-A1 | Crystalline imidazole-5-carboxylic acid derivative | UACA, MAP1LC3C, TBCA | AGTR2 1204/4885AGTR1 1162/4885GP6 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.